Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
354,80 €
+5,60 €
+1,60%
30.04.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,93%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

16.02.26 - GlobeNewswire
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous ...
07.02.26 - GlobeNewswire
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-​breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-​inferiority compared to the current standard of ...
29.01.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Group sales grew by 7% 1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by ...
29.01.26 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
Konzernverkäufe stiegen um 7% 1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und diagnostischen Lösungen. Im vierten Quartal ...
27.01.26 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-​weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-​adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved ...
22.12.25 - Maximilian Berger
ROCHE HOLDING AG GS steht still – ich rieche Bewegung!
Die Roche-​Aktie (WKN 855167) zeigt sich robust. Was Anleger zur aktuellen Kursentwicklung, Bewertung und Zukunftschancen wissen sollten.
22.12.25 - GlobeNewswire
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and ...
11.12.25 - GlobeNewswire
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug ...
10.12.25 - GlobeNewswire
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-​free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years 1-3 ...
09.12.25 - ARIVA.DE Redaktion
Neuer Geheimtipp aus der Biotech-Szene – dieser Wert hat sich zu Wochenbeginn mehr als verdoppelt!
Ist ein neuer Abnehm-​Star geboren? Wave Life Sciences könnte mit einem bisher einzigartigen Wirkstoff den Adipositas-​Markt aufmischen. Ein Ansatz, der Fett abbaut, Muskeln ...
09.12.25 - GlobeNewswire
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida ...
09.12.25 - GlobeNewswire
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-...
08.12.25 - GlobeNewswire
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-​arm US cohort of phase III ...
08.12.25 - GlobeNewswire
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx 1 This Columvi combination is available off-the-...
02.12.25 - GlobeNewswire
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
The point-​of-care test delivers PCR-​accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications and onward transmission. ...
19.11.25 - GlobeNewswire
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
Lunsumio provides high rates of deep and long-​lasting responses in third-​line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient ...
18.11.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-​of-care endocrine monotherapy These unprecedented ...
10.11.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal ...
03.11.25 - GlobeNewswire
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline ...
03.11.25 - GlobeNewswire
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »